{"cited_by_count":3492515,"description":"This cluster of papers focuses on the advances in cancer immunotherapy research, particularly in the context of immune checkpoint blockade targeting PD-1 and PD-L1, the impact of tumor microenvironment, biomarkers for immunotherapy response, T-cell exhaustion, neoantigens, tumor mutational burden, immune-related adverse events, and the exploration of combination therapies. The research also delves into the intricate mechanisms of cancer immunoediting.","display_name":"Cancer Immunotherapy and Biomarkers","domain_id":"4","external_ids":{"openalex":"https://openalex.org/T10158","wikipedia":"https://en.wikipedia.org/wiki/Cancer_immunotherapy"},"field_id":"27","id":"T10158","keywords":[{"display_name":"immune checkpoint inhibitors","id":"immune-checkpoint-inhibitors","score":0.5056,"url":"https://openalex.org/keywords/immune-checkpoint-inhibitors"},{"display_name":"cancer immunotherapy","id":"cancer-immunotherapy","score":0.2416,"url":"https://openalex.org/keywords/cancer-immunotherapy"},{"display_name":"immune-related adverse events","id":"immune-related-adverse-events","score":0.6792,"url":"https://openalex.org/keywords/immune-related-adverse-events"},{"display_name":"nivolumab","id":"nivolumab","score":0.5354,"url":"https://openalex.org/keywords/nivolumab"},{"display_name":"pembrolizumab","id":"pembrolizumab","score":0.4548,"url":"https://openalex.org/keywords/pembrolizumab"},{"display_name":"tumor immune microenvironment","id":"tumor-immune-microenvironment","score":0.2879,"url":"https://openalex.org/keywords/tumor-immune-microenvironment"},{"display_name":"PD-L1","id":"pd-l1","score":0.3841,"url":"https://openalex.org/keywords/pd-l1"},{"display_name":"immune checkpoint blockade","id":"immune-checkpoint-blockade","score":0.5429,"url":"https://openalex.org/keywords/immune-checkpoint-blockade"},{"display_name":"anti-PD-1 therapy","id":"anti-pd-1-therapy","score":0.564,"url":"https://openalex.org/keywords/anti-pd-1-therapy"},{"display_name":"tumor-infiltrating lymphocytes","id":"tumor-infiltrating-lymphocytes","score":0.288,"url":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes"},{"display_name":"combination immunotherapy","id":"combination-immunotherapy","score":0.4731,"url":"https://openalex.org/keywords/combination-immunotherapy"},{"display_name":"PD-L1 expression","id":"pd-l1-expression","score":0.4701,"url":"https://openalex.org/keywords/pd-l1-expression"},{"display_name":"PD-1","id":"pd-1","score":0.3872,"url":"https://openalex.org/keywords/pd-1"},{"display_name":"ipilimumab","id":"ipilimumab","score":0.6084,"url":"https://openalex.org/keywords/ipilimumab"},{"display_name":"PD-1 inhibitors","id":"pd-1-inhibitors","score":0.445,"url":"https://openalex.org/keywords/pd-1-inhibitors"},{"display_name":"tumor mutational burden","id":"tumor-mutational-burden","score":0.3293,"url":"https://openalex.org/keywords/tumor-mutational-burden"},{"display_name":"tumor immune evasion","id":"tumor-immune-evasion","score":0.2944,"url":"https://openalex.org/keywords/tumor-immune-evasion"},{"display_name":"CTLA-4","id":"ctla-4","score":0.3187,"url":"https://openalex.org/keywords/ctla-4"},{"display_name":"metastatic melanoma","id":"metastatic-melanoma","score":0.2252,"url":"https://openalex.org/keywords/metastatic-melanoma"},{"display_name":"immune checkpoint","id":"immune-checkpoint","score":0.3533,"url":"https://openalex.org/keywords/immune-checkpoint"},{"display_name":"T cell exhaustion","id":"t-cell-exhaustion","score":0.2734,"url":"https://openalex.org/keywords/t-cell-exhaustion"},{"display_name":"PD-L1 inhibitors","id":"pd-l1-inhibitors","score":0.5233,"url":"https://openalex.org/keywords/pd-l1-inhibitors"},{"display_name":"immunotherapy resistance","id":"immunotherapy-resistance","score":0.4459,"url":"https://openalex.org/keywords/immunotherapy-resistance"},{"display_name":"immunotherapy response","id":"immunotherapy-response","score":0.3002,"url":"https://openalex.org/keywords/immunotherapy-response"},{"display_name":"atezolizumab","id":"atezolizumab","score":0.3811,"url":"https://openalex.org/keywords/atezolizumab"}],"legacy_keywords":["Immune Checkpoint Blockade","PD-1 and PD-L1","Tumor Microenvironment","Tumor Mutational Burden","Immune-related Adverse Events","T-cell Exhaustion","Neoantigens","Biomarkers for Immunotherapy","Combination Therapies","Cancer Immunoediting"],"openalex_id":"https://openalex.org/T10158","source_created_date":"2024-01-23T15:27:05","source_updated_date":"2026-10-17T03:02:00","subfield_id":"2730","url":"/topics/T10158","works_api_url":"https://api.openalex.org/works?filter=topics.id:T10158","works_count":182796,"label":"Cancer Immunotherapy and Biomarkers","provider":"openalex","revision":"8e61cf212aea90e1","taxonomy_revision":"f050b5d4780b1289","title":"Cancer Immunotherapy and Biomarkers","kind":"topic-directory","aeo_cohort":"topic-directory","catalogue_revision":"f050b5d4780b1289","numeric_address":"36108824083622370","address_version":"morton4x16-v1","coordinates":[4,27,2730,10158],"answer_status":"Directory metadata; local answer requires separate source review","truth_status":"Subject descriptor, not a factual answer or a demonstrated knowledge gap","reviewed_answer":null}